Science Center Appoints Edward L. Erickson Venture Partner.

PHILADELPHIA -- The Science Center, a total "Venture Ecosystem[TM]" for developing life sciences and technology ventures, announced today the appointment of Edward L. Erickson as a Venture Partner with Sc Capital Partners, the Center's venture capital fund, which invests in promising new life science and technology companies.

Erickson has served as president, CEO, or director of nine medical products companies, four of which successfully completed an initial public offering (IPO) under his leadership. Throughout his career, he has raised approximately $500 million in equity and debt capital in both the private and public capital markets. In addition to medical products companies, he has experience in the information technology, energy and defense industries.

"Ed is a great addition to Sc Capital Partners and the Science Center," said Dr. Pradip K. Banerjee, president and chief executive officer of the Science Center. "His innovative management approach and investment experience will provide our companies with valuable industry expertise, resulting in wealth creation for our entrepreneurs, Sc Capital Partners, the Science Center and the Greater Philadelphia region."

Erickson currently serves as non-executive Chairman of the Board of Immunicon Corporation {NASDAQ:IMMC}, a medical products company developing diagnostic and research products for rare cell analysis and molecular research, with an initial focus on cancer. He joined Immunicon's board of directors in 1998, and served as CEO from 1999-2005. Immunicon completed an IPO in 2004.

From 1993 to 1998, Erickson was President and CEO of DepoTech Corporation, a biopharmaceutical company in the drug delivery field. DepoTech completed an IPO in 1995. From 1991 to 1993, he was President and CEO of Cholestech Corporation, a diagnostics company in point-of-care cholesterol testing and screening. Colestech completed an IPO in 1992. Previously, he held senior management positions with The Ares-Serono Group (now Serono, S.A.), a pharmaceutical company based in Switzerland, and Amersham International, now a unit of GE, then a publicly-traded, diversified healthcare and life science research products company in the UK.

Mr. Erickson is also currently a director of Barrier Therapeutics, Inc. {NASDAQ:BTRX}, a pharmaceutical company focused on the discovery, development, and commercialization of dermatological products; BioTrove, Inc., a life sciences company with proprietary technology for drug discovery, drug development and diagnostic applications; and Valeo Medical, Inc., which is developing diagnostic tests for endometriosis.

Erickson holds a Bachelor of Science with distinction in Mathematics with a minor in Physics and an MS in Mathematics from the Illinois Institute of Technology. He received a Master's in Business Administration with high distinction from Harvard University, where he was elected a Baker Scholar, and was awarded the Loeb Rhodes Fellowship in Finance. He served as an officer in the U.S. Navy's Nuclear Power Program, and served aboard the USS Nautilus, the world's first nuclear submarine.

"I look forward to my work establishing and supporting entrepreneurial companies through Sc Capital Partners." Erickson said. "The Science Center is a highly innovative organization for economic growth, and I'm delighted to help develop some of the most exciting and promising technologies of the 21st Century."

About Sc Capital Partners

Sc Capital Partners invests in promising and sustainable new technologies in the life science and technology industries. Sc Capital Partners seeks to identify promising opportunities and fuel their growth with resources from a variety of sources. We work with companies through SC Ventures to define their capital needs and to identify the best sources and staging of these funds.

ABOUT THE SCIENCE CENTER

The Science Center (www.ScienceCenter.org) is a "total venture ecosystem" that forms and funds early-stage life science and technology companies, accelerates their commercialization and provides the infrastructure and community they need to flourish. It offers specialized wet and dry laboratory facilities, turn-key management services, a $10 million Venture fund and an experienced real estate management team. Situated on 1.7 million sq. ft. of real estate on Market Street, adjacent to all of Philadelphia's major universities and medical research institutions, Science Center is positioned in a unique vantage point for creating powerful companies by bringing together strong science and scientists, entrepreneurs, managers, grants and investment capital. Science Center is an attractive "soft landing" place for international companies to launch their US businesses, and is a powerful economic engine for the regional economy. Since 2002, companies started at Science Center have attracted more than $300 million in additional private investments. The Science Center received the Outstanding Research/Science Park of the Year award by the Association of University Research Parks (AURP). AURP recognizes research parks that excel in bringing technology from the laboratory to commercially viable business activities, and promoting the growth of businesses, jobs and public revenue.